Year-End MATCH (DEADLINE Dec 31): Donate & Make a Difference | Donate
NCCS submitted comments to the Departments of the Treasury and Health and Human Services and the Centers for Medicare and Medicaid Services (CMS) on the proposed Notice of Benefit and Payment Parameters (NBPP) for 2022, the annual rule governing core provisions of the Affordable Care Act (ACA), including the operation of the marketplaces, standards for […]
The National Coalition for Cancer Survivorship (NCCS) joined with the Cancer Leadership Council (CLC) in urging Health and Human Services Secretary-Designate Xavier Becerra to protect Medicare beneficiaries’ access to Part D drugs in six protected classes, which include certain cancer treatments. In January, the Centers for Medicare and Medicaid Services (CMS) issued a request for […]
The National Coalition for Cancer Survivorship (NCCS) joined other member organizations of the Cancer Leadership Council (CLC) in a letter to Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma, urging “immediate action” by CMS to withdraw an interim final rule that implements a most favored nation (MFN) model in Medicare Part B drug […]
The National Coalition for Cancer Survivorship (NCCS) recently submitted comments urging the Department of Health and Human Services (HHS) to withdraw a recent proposed rule that would require the review of HHS rules that are more than 10 years old. If implemented, this proposed rule would automatically eliminate regulations that are 10 years old or […]
NCCS recently submitted a comment letter to the Centers for Medicare and Medicaid (CMS) regarding the Medicare physician fee schedule for calendar year 2021. The comment letter focuses on telehealth-related provisions of the proposed rule, as we are learning from our findings from our Telehealth Project that both patients and providers need more tools and […]
The National Coalition for Cancer Survivorship (NCCS) submitted comments in response to an Informal Request for Information on the proposed Oncology Care First Model. This model was released by the Centers for Medicare and Medicaid Services (CMS). The comments focus on concerns regarding adequate resources in the model to support high quality cancer care. The letter also identifies shortcomings in the model that could influence […]
NCCS and member organizations of the Cancer Leadership Council (CLC) submitted comments to the HHS in response to the agency’s Notice of Benefits and Payment Parameters for 2020. The Notice contains rules and provisions that will apply to the individual market (the Affordable Care Act marketplace), and small group health insurance markets. The letter states NCCS’ concerns about specific provisions that may threaten cancer patients’ access […]
The Department of Health and Human Services (HHS) released recently a proposed rule to change Medicare Part D’s protected classes drug coverage. In response, NCCS joined with other patient and provider groups of the Cancer Leadership Council (CLC) to comment on how these proposed changes could impact patients. The proposed rule would give Medicare plans the option to limit coverage of drugs in six categories, including cancer drugs. […]
On December 31st, NCCS submitted our final comment letter of the year to the Centers for Medicare and Medicaid Services regarding the advance notice of proposed rulemaking for the Medicare Part B drug program.
In the letter, we outlined concerns that this proposal could have on Medicare beneficiaries such as impacts on patient access to innovative therapies, as well as concerns regarding the enormous scope of the test. NCCS suggested […]
NCCS joined with other cancer organizations of the Cancer Leadership Council (CLC) in a letter to the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) regarding the new plan announced on August 7 that gives Medicare Advantage plans the option of applying step therapy for physician-administered and other Part B drugs. The letter outlines several concerns regarding the application of step therapy […]
We are relentless in improving the quality of care and life after a cancer diagnosis. Your support makes all the difference right now.
Together we can improve cancer care for survivors! Sign up to be the first to know about cancer policy issues and ways to take action
National Coalition for Cancer Survivorship
8455 Colesville Road | Suite 930 | Silver Spring, MD 20910
877-NCCS-YES | info@canceradvocacy.org
Privacy Policy | Terms and Conditions
Copyright © 1995-2021 by the National Coalition for Cancer Survivorship
National Coalition for Cancer Survivorship, NCCS, Cancer Survival Toolbox, and related Logos are registered in the United States as trademarks of the National Coalition for Cancer Survivorship.
Be the first to hear about cancer policy and survivorship issues! Subscribe and receive the biweekly NCCS Health Care Roundup, invites to webinars and events, and more.
Founder
Northeast Regional Cancer Institute
“Perhaps one of the most impactful collaborations in Dr. Brereton’s extraordinary career remains his early work and long friendship with Ellen Stovall. Through him, and in turn through the thousands of lives he has touched, Ellen’s work continues, and her mission lives on.”
—Karen M. Saunders
President, Northeast Regional Cancer Institute